Search Results - "Cephalalgia"

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Get more information

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial by Skljarevski, Vladimir, Matharu, Manjit, Millen, Brian A, Ossipov, Michael H, Kim, Byung-Kun, Yang, Jyun Yan

“…Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention. Methods A global,…”
Get more information

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine by Dodick, David W, Ashina, Messoud, Brandes, Jan Lewis, Kudrow, David, Lanteri-Minet, Michel, Osipova, Vera, Palmer, Kerry, Picard, Hernan, Mikol, Daniel D, Lenz, Robert A

“…Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the…”
Get more information

The International Classification of Headache Disorders, 3rd edition (beta version)

Get more information

Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution by Caronna, Edoardo, Ballvé, Alejandro, Llauradó, Arnau, Gallardo, Victor José, Ariton, Diana María, Lallana, Sofia, López Maza, Samuel, Olivé Gadea, Marta, Quibus, Laura, Restrepo, Juan Luis, Rodrigo-Gisbert, Marc, Vilaseca, Andreu, Hernandez Gonzalez, Manuel, Martinez Gallo, Monica, Alpuente, Alicia, Torres-Ferrus, Marta, Pujol Borrell, Ricard, Alvarez-Sabin, José, Pozo-Rosich, Patricia

“…To define headache characteristics and evolution in relation to COVID-19 and its inflammatory response. This is a prospective study, comparing clinical data…”
Get more information

Trigeminal neuralgia - diagnosis and treatment by Maarbjerg, Stine, Di Stefano, Giulia, Bendtsen, Lars, Cruccu, Giorgio

“…Introduction Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in one or more divisions of the trigeminal…”
Get more information

Temporomandibular disorders: Old ideas and new concepts by List, Thomas, Jensen, Rigmor Højland

“…Background Temporomandibular disorders (TMD) is an umbrella term for pain and dysfunction involving the masticatory muscles and the temporomandibular joints…”
Get more information

Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial by Reuter, Uwe, Ehrlich, Marc, Gendolla, Astrid, Heinze, Axel, Klatt, Jan, Wen, Shihua, Hours-Zesiger, Peggy, Nickisch, Jacqueline, Sieder, Christian, Hentschke, Christian, Maier-Peuschel, Monika

“…We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for…”
Get more information

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis by Hepp, Zsolt, Dodick, David W, Varon, Sepideh F, Chia, Jenny, Matthew, Nitya, Gillard, Patrick, Hansen, Ryan N, Devine, Emily Beth

“…Background Migraine prevention guidelines recommend oral prophylactic medications for patients with frequent headache. This study examined oral migraine…”
Get more information

Adherence to oral migraine-preventive medications among patients with chronic migraine by Hepp, Zsolt, Dodick, David W, Varon, Sepideh F, Gillard, Patrick, Hansen, Ryan N, Devine, Emily B

“…Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life…”
Get more information

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine by Voss, Tiffini, Lipton, Richard B, Dodick, David W, Dupre, Nicole, Ge, Joy Yang, Bachman, Robert, Assaid, Christopher, Aurora, Sheena K, Michelson, David

“…The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA),…”
Get more information

Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial by Chou, Denise E, Shnayderman Yugrakh, Marianna, Winegarner, Dana, Rowe, Vernon, Kuruvilla, Deena, Schoenen, Jean

“…To assess the safety and efficacy of external trigeminal nerve stimulation for acute pain relief during migraine attacks with or without aura via a…”
Get more information

Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study by Goadsby, Peter J, de Coo, Ilse F, Silver, Nicholas, Tyagi, Alok, Ahmed, Fayyaz, Gaul, Charly, Jensen, Rigmor H, Diener, Hans-Christoph, Solbach, Kasia, Straube, Andreas, Liebler, Eric, Marin, Juana Ca, Ferrari, Michel D

“…Background Clinical observations and results from recent studies support the use of non-invasive vagus nerve stimulation (nVNS) for treating cluster headache…”
Get more information

Perceived triggers of primary headache disorders: A meta-analysis by Pellegrino, A Brooke Walters, Davis-Martin, Rachel E, Houle, Timothy T, Turner, Dana P, Smitherman, Todd A

“…Objective To quantitatively synthesize extant literature on perceived triggers of primary headache disorders. Methods A meta-analytic review of headache…”
Get more information

Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study by Gaul, Charly, Diener, Hans-Christoph, Silver, Nicholas, Magis, Delphine, Reuter, Uwe, Andersson, Annelie, Liebler, Eric J, Straube, Andreas

“…Chronic cluster headache (CH) is a debilitating disorder for which few well-controlled studies demon.strate effectiveness of available therapies. Non-invasive…”
Get more information

Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia by Rocha-Filho, Pedro Augusto Sampaio, Magalhães, João Eudes

“…To assess the frequency and characteristics of headache in patients with COVID-19 and whether there is an association between headache and anosmia and ageusia…”
Get more information

Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Messina, Roberta, Huessler, Eva-Maria, Puledda, Francesca, Haghdoost, Faraidoon, Lebedeva, Elena R, Diener, Hans-Christoph

“…Direct comparisons of the tolerability and safety of migraine preventive treatments targeting the calcitonin gene-related peptide pathway are lacking. This…”
Get more information

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study by Ashina, Messoud, Tepper, Stewart, Brandes, Jan Lewis, Reuter, Uwe, Boudreau, Guy, Dolezil, David, Cheng, Sunfa, Zhang, Feng, Lenz, Robert, Klatt, Jan, Mikol, Daniel D

“…Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly…”
Get more information

Migraine therapeutics differentially modulate the CGRP pathway by Bhakta, Minoti, Vuong, Trang, Taura, Tetsuya, Wilson, David S, Stratton, Jennifer R, Mackenzie, Kimberly D

“…The clinical efficacy of migraine therapeutic agents directed towards the calcitonin-gene related peptide (CGRP) pathway has confirmed the key role of this…”
Get more information

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study by Overeem, Lucas Hendrik, Peikert, Andreas, Hofacker, Maxi Dana, Kamm, Katharina, Ruscheweyh, Ruth, Gendolla, Astrid, Raffaelli, Bianca, Reuter, Uwe, Neeb, Lars

“…Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal…”
Get more information